Frontlight ResearchEarly access
Not yet taking people in United StatesNo phase
Tracing Of Real-time glu13Cose Metabolism in Human Immune Cells - Intensive Care Unit
Key facts
- Who runs it
- Vanderbilt University Medical Center
- Where
- Nashville, United StatesSee the site
- Trial code
- Status
- Not yet recruiting
- People taking part
- 25 people, planned
- Started
- 1 Nov 2026
- Expected to end
- 1 Mar 2028
- Type of study
- Interventional
- Treatments tested
- 13C6-Glucose
- Record updated
- 9 September 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Adults aged 18 or older
- Admitted to one of the following VUMC adult ICUs: Medical ICU, Pulmonary ICU
- The participant or legally authorized representative must agree to the genetic analyses required as part of this study
Who cannot take part
- Hemoglobin less than 8 g/dL
- Uncontrolled hyperglycemia (persistent blood glucose >300 mg/dL) or any clinical condition in which additional IV glucose administration is not appropriate in the opinion of the Study Coordinator, PI, or treating ICU team
- Pregnant
- Prisoner or in police custody
- Patient desires comfort measures only or has a goals-of-care plan inconsistent with participation in non-beneficial research procedures
- Current participation in another study where the total volume of blood drawn, when added to this study blood draw volume, exceeds 500 mL in an 8-week period
- Unable to safely obtain vascular access required for study infusion and blood collection
- Clinical instability or anticipated clinical care needs that would make the study procedure inappropriate at that time in the opinion of the Study Coordinator, PI, or treating ICU team
- Any medical issue or pharmacologic exposure which, in the opinion of the study investigator, might interfere with the study objectives
- Any reason which, in the opinion of the study investigator, adds additional risk to the patient
Where in United States
- Vanderbilt University Medical CenterNashville, United StatesContact: Matthew T Stier, M.D., Ph.D.Not yet recruiting
About the trial
What the trial wants to find out
The purpose of this study is to understand how cells of the immune system use the common sugar glucose during critical illness. Investigators will intravenously infuse a non-radioactive carbon-13 glucose tracer into adult intensive care unit (ICU) participants over a few hours and collect immune cells from the blood to track uptake and usage of this glucose within these immune cells.
The group in the trial
- 13C6-GlucoseOther group
Participants will receive 10-25 grams of 13C6-glucose intravenously over 2-4 hours during a single ICU study procedure.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 9 September 2026